| scholarly article | Q13442814 |
| P2093 | author name string | A R Marks | |
| M Poon | |||
| J J Badimon | |||
| R Gallo | |||
| S O Marx | |||
| M B Taubman | |||
| P2860 | cites work | FK506 binding protein associated with the calcium release channel (ryanodine receptor) | Q24292729 |
| Molecular cloning and overexpression of the human FK506-binding protein FKBP | Q24302504 | ||
| Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12 | Q24305896 | ||
| Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin | Q27860688 | ||
| A mammalian protein targeted by G1-arresting rapamycin-receptor complex | Q28243712 | ||
| Epidermal growth factor induces rapid reorganization of the actin microfilament system in human A431 cells | Q28261188 | ||
| Solution Structure of FKBP, a Rotamase Enzyme and Receptor for FK506 and Rapamycin | Q28273170 | ||
| Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast | Q28277565 | ||
| RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs | Q28286431 | ||
| Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase | Q28320515 | ||
| cDNA encoding murine FK506-binding protein (FKBP): nucleotide and deduced amino acid sequences | Q28588780 | ||
| Immunophilin FK506 binding protein associated with inositol 1,4,5-trisphosphate receptor modulates calcium flux | Q28609357 | ||
| The pathogenesis of atherosclerosis: a perspective for the 1990s | Q29547827 | ||
| Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells. Role of Ca2+ mobilization and protein kinase C activation | Q33890331 | ||
| Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation | Q34133504 | ||
| Structural organization of the genes encoding human and murine FK506-binding protein (FKBP) 13 and comparison to FKBP1. | Q34290748 | ||
| Probing Immunosuppressant Action with a Nonnatural Immunophilin Ligand | Q34569267 | ||
| Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells | Q34719651 | ||
| Attachment of smooth muscle cells to collagen and their migration toward platelet-derived growth factor | Q35381355 | ||
| Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty | Q35597681 | ||
| Migration of smooth muscle and endothelial cells. Critical events in restenosis | Q35783147 | ||
| The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty | Q37694282 | ||
| Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands | Q40794230 | ||
| Cellular functions of immunophilins | Q41075701 | ||
| Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin | Q41412030 | ||
| Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein | Q41467443 | ||
| Regulation of chemotaxis by the platelet-derived growth factor receptor-beta | Q41488423 | ||
| Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase | Q41608842 | ||
| Inhibition of calcineurin by a novel FK-506-binding protein. | Q51131963 | ||
| Diacylglycerol-stimulated formation of actin nucleation sites at plasma membranes | Q54382866 | ||
| Cardiac transplant atherosclerosis | Q68177290 | ||
| Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF | Q68252685 | ||
| Significance of quiescent smooth muscle migration in the injured rat carotid artery | Q70049140 | ||
| Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels | Q70775037 | ||
| A platelet-derived factor chemotactic for rabbit arterial smooth muscle cells in culture | Q71030700 | ||
| Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation | Q72019019 | ||
| Role of calcium/calmodulin-dependent protein kinase II in the regulation of vascular smooth muscle cell migration | Q72532997 | ||
| The ryanodine receptor from canine heart sarcoplasmic reticulum is associated with a novel FK-506 binding protein | Q72748127 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sirolimus | Q32089 |
| cell migration | Q189092 | ||
| P304 | page(s) | 2277-2283 | |
| P577 | publication date | 1996-11-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Rapamycin inhibits vascular smooth muscle cell migration | |
| P478 | volume | 98 |
| Q57058252 | 40 Years of Percutaneous Coronary Intervention: History and Future Directions |
| Q42289915 | A Finite Element Study on Variations in Mass Transport in Stented Porcine Coronary Arteries Based on Location in the Coronary Arterial Tree |
| Q87268775 | A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients |
| Q36650845 | AKT2 Confers Protection Against Aortic Aneurysms and Dissections |
| Q90084018 | Activation of TFEB ameliorates dedifferentiation of arterial smooth muscle cells and neointima formation in mice with high-fat diet |
| Q40847236 | An in silico study on the role of smooth muscle cell migration in neointimal formation after coronary stenting. |
| Q44636622 | Angiographic regression of cardiac allograft vasculopathy after introducing sirolimus immunosuppression. |
| Q54982216 | Anti-Inflammatory Effect of Gallic Acid-Eluting Stent in a Porcine Coronary Restenosis Model. |
| Q50703978 | Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells |
| Q39726482 | Biodegradable sirolimus-loaded poly(lactide) nanoparticles as drug delivery system for the prevention of in-stent restenosis in coronary stent application |
| Q36849059 | Bone marrow-derived immune cells regulate vascular disease through a p27(Kip1)-dependent mechanism |
| Q34981345 | CDKs and CKIs: molecular targets for tissue remodelling |
| Q40565449 | Cell-cycle-dependent regulation of cell motility and determination of the role of Rac1. |
| Q41384637 | Chronic allograft rejection: A significant hurdle to transplant success |
| Q48266029 | Comparison of dextran-based sirolimus-eluting stents and PLA-based sirolimus-eluting stents in vitro and in vivo |
| Q51810073 | Comparison of the performance of zotarolimus- and everolimus-eluting stents by optical coherence tomography and coronary angioscopy |
| Q36569798 | Coronary artery restenosis: vascular biology and emerging therapeutic strategies |
| Q34747489 | Coronary artery stents: evaluating new designs for contemporary percutaneous intervention |
| Q38093501 | Coronary stents: historical development, current status and future directions |
| Q34181796 | Current treatment practice in immunosuppression |
| Q46870633 | Cytostatic drugs differentially affect phenotypic features of porcine coronary artery smooth muscle cell populations |
| Q36333923 | Diabetes and percutaneous coronary intervention in the setting of an acute coronary syndrome |
| Q44632267 | Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E-deficient mice |
| Q45193067 | Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling. |
| Q28219254 | Drug-eluting stent: a review and update |
| Q37144221 | Drug-eluting stents - what should be improved? |
| Q35148405 | Drug-eluting stents for cardiovascular disorders |
| Q43900398 | Drug-eluting stents for the prevention of restenosis: in quest for the Holy Grail |
| Q35945466 | Drug-eluting stents: a mechanical and pharmacologic approach to coronary artery disease |
| Q35218995 | Drug-eluting stents: from bench to bed. |
| Q42369326 | Dual TORCs driven and B56 orchestrated signaling network guides eukaryotic cell migration. |
| Q44319147 | Effect of carvedilol alone or in the presence of cyclosporine on the migration of vascular smooth muscle cell of rat. |
| Q34660679 | Effect of everolimus on pre-existing atherosclerosis in LDL-receptor deficient mice |
| Q43640432 | Effect of p27 deficiency and rapamycin on intimal hyperplasia: in vivo and in vitro studies using a p27 knockout mouse model |
| Q53213529 | Effect of recombinant human SDF-1a on re-endothelialization after sirolimus-eluting stent implantation in rabbit aorta abdominalis |
| Q44454391 | Effect of systemic immunosuppression on coronary in-stent intimal hyperplasia in renal transplant patients |
| Q37261896 | Effects of an immunosuppressive treatment on the rat prostate |
| Q36549186 | Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors |
| Q46931316 | Effects of controlled-released sirolimus from polymer matrices on human coronary artery smooth muscle cells |
| Q28361022 | Effects of local cytochalasin D delivery on smooth muscle cell migration and on collar-induced intimal hyperplasia in the rabbit carotid artery |
| Q35771807 | Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials |
| Q47862043 | Eluting characteristics of a platelet glycoprotein receptor antibody using a PLLA-coated stent. |
| Q37588002 | Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era. |
| Q51189916 | Empiric switch from calcineurin inhibitor to sirolimus-based immunosuppression in pediatric heart transplantation recipients |
| Q44193423 | Fate of side branches after coronary arterial sirolimus-eluting stent implantation |
| Q45004968 | From sirolimus to the Cypher stent: stages of the victory against restenosis |
| Q54383689 | Granulocyte-macrophage colony-stimulating factor (GM-CSF): a chemoattractive agent for murine leukocytes in vivo |
| Q37859760 | How Safe and How Good are drug-eluting stents? |
| Q33810041 | Impaired peroxisome proliferator-activated receptor-gamma contributes to phenotypic modulation of vascular smooth muscle cells during hypertension |
| Q26863422 | Implications of autophagy for vascular smooth muscle cell function and plasticity |
| Q50021291 | In vitro mutagenicity and blood compatibility of paclitaxel and curcumin in poly (dl-lactide-co-glicolide) films |
| Q33691133 | In-vitro Release of Rapamycin from a Thermosensitive Polymer for the Inhibition of Vascular Smooth Muscle Cell Proliferation |
| Q47639140 | Inhibition of 5-Hydroxytryptamine Receptor 2B Reduced Vascular Restenosis and Mitigated the β-Arrestin2-Mammalian Target of Rapamycin/p70S6K Pathway |
| Q37865784 | Inhibition of human in-stent restenosis: a molecular view |
| Q38954597 | Inhibition of the mTOR pathway in abdominal aortic aneurysm: implications of smooth muscle cell contractile phenotype, inflammation, and aneurysm expansion |
| Q40909332 | Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells |
| Q36977876 | Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors |
| Q37969504 | Liposomal alendronate for the treatment of restenosis |
| Q34566559 | Loss of Canonical Insulin Signaling Accelerates Vascular Smooth Muscle Cell Proliferation and Migration Through Changes in p27Kip1 Regulation |
| Q41424778 | Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor |
| Q41894403 | Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo. |
| Q28654633 | Macromolecular approaches to prevent thrombosis and intimal hyperplasia following percutaneous coronary intervention |
| Q77522059 | Medical therapies for the prevention of restenosis after percutaneous coronary interventions |
| Q45056952 | MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer |
| Q45330530 | MicroRNA‐21 mediates the rapamycin‐induced suppression of endothelial proliferation and migration |
| Q54964181 | Migration of airway smooth muscle cells |
| Q36861726 | Modeling and rescue of the vascular phenotype of Williams-Beuren syndrome in patient induced pluripotent stem cells |
| Q61510088 | Modulation of apoptosis, proliferation, and p27 expression in a porcine coronary angioplasty model |
| Q34192264 | Monitoring molecular-specific pharmacodynamics of rapamycin in vivo with inducible Gal4->Fluc transgenic reporter mice |
| Q34778754 | Morelloflavone blocks injury-induced neointimal formation by inhibiting vascular smooth muscle cell migration. |
| Q33997601 | Motility, Survival, and Proliferation |
| Q57366868 | Multiple noncovalent interactions mediated one-pot therapeutic assemblies for the effective treatment of atherosclerosis |
| Q45953204 | New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles. |
| Q34609660 | New approaches to immunosuppression in liver transplantation. |
| Q35190937 | New approaches to preventing restenosis |
| Q44120112 | No delayed restenosis at 18 months after implantation of sirolimus-eluting stent |
| Q37218108 | Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors |
| Q54979024 | Notoginsenoside R1 inhibits vascular smooth muscle cell proliferation, migration and neointimal hyperplasia through PI3K/Akt signaling. |
| Q47660630 | Opposing Actions of AKT (Protein Kinase B) Isoforms in Vascular Smooth Muscle Injury and Therapeutic Response |
| Q28548405 | Optimization of Drug Delivery by Drug-Eluting Stents |
| Q43247378 | Oral rapamycin attenuates atherosclerosis without affecting the arterial responsiveness of resistance vessels in apolipoprotein E-deficient mice |
| Q44533617 | Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice |
| Q34544955 | Overcoming restenosis with sirolimus: from alphabet soup to clinical reality |
| Q82207320 | Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells |
| Q39505785 | Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement |
| Q43148850 | Perivascular fat-mediated vascular dysfunction and remodeling through the AMPK/mTOR pathway in high-fat diet-induced obese rats |
| Q36346487 | Pharmacological basis of different targets for the treatment of atherosclerosis. |
| Q38241974 | Pharmacological inhibition of coronary restenosis: systemic and local approaches |
| Q37756979 | Pharmacological prevention and management of restenosis |
| Q36179679 | Pharmacological treatment for prevention of restenosis |
| Q40944784 | Phosphorylation of GATA-6 is required for vascular smooth muscle cell differentiation after mTORC1 inhibition |
| Q42425209 | Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices |
| Q47769116 | Platelet-Derived Growth Factor-BB, Insulin-like Growth Factor-I, and Phorbol Ester Activate Different Signaling Pathways for Stimulation of Vascular Smooth Muscle Cell Migration |
| Q33806770 | Potential utility of rapamycin and tacrolimus in long-term, low-toxicity regimens |
| Q37709401 | Predictive value of C-reactive protein after drug-eluting stent implantation |
| Q50963092 | Preparation and characterization of rapamycin-loaded PLGA coating stent |
| Q35938663 | Preventing restenosis in early drug-eluting stent era: recent developments and future perspectives |
| Q36752004 | Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation. |
| Q43934801 | Quantification of sirolimus by liquid chromatography-tandem mass spectrometry using on-line solid-phase extraction |
| Q42834164 | RNAi-based functional selection identifies novel cell migration determinants dependent on PI3K and AKT pathways |
| Q33848041 | Rapamune does not attenuate high cholesterol-induced atherosclerosis in rabbits |
| Q35677930 | Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice |
| Q43016836 | Rapamycin eluting stent: the onset of a new era in interventional cardiology |
| Q44368238 | Rapamycin inhibits E2F-dependent expression of minichromosome maintenance proteins in vascular smooth muscle cells |
| Q40277182 | Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways |
| Q40459006 | Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin. |
| Q33776274 | Rapamycin inhibits re-endothelialization after percutaneous coronary intervention by impeding the proliferation and migration of endothelial cells and inducing apoptosis of endothelial progenitor cells |
| Q44755124 | Rapamycin plays a new role as differentiator of vascular smooth muscle phenotype. focus on "The mTOR/p70 S6K1 pathway regulates vascular smooth muscle differentiation". |
| Q46972339 | Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling |
| Q84058519 | Rapamycin-Loaded Nanoparticles for Inhibition of Neointimal Hyperplasia in Experimental Vein Grafts |
| Q35047621 | Rapamycin-loaded nanoparticles for inhibition of neointimal hyperplasia in experimental vein grafts |
| Q44437992 | Rapamycin: signaling in vascular smooth muscle |
| Q38620803 | Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potential. |
| Q36701571 | Relative resistance to Mammalian target of rapamycin inhibition in vascular smooth muscle cells of diabetic donors |
| Q35579442 | Review series: TOR kinase complexes and cell migration |
| Q37824477 | Role of mTOR signaling in tumor cell motility, invasion and metastasis |
| Q35584915 | Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial). |
| Q54742299 | Role of smooth muscle cell migration and proliferation in allograft vascular disease. |
| Q42828877 | Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration |
| Q44420391 | Sirolimus (Rapamycin) Monotherapy Prevents Graft Vascular Disease in Nonhuman Primate Recipients of Orthotopic Aortic Allografts |
| Q54466185 | Sirolimus and Cardiovascular Disease Risk in Liver Transplantation |
| Q53393195 | Sirolimus as Primary Immunosuppression Attenuates Allograft Vasculopathy With Improved Late Survival and Decreased Cardiac Events After Cardiac Transplantation |
| Q44436724 | Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications |
| Q41734239 | Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM |
| Q44437969 | Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients |
| Q44605351 | Sirolimus for the Prevention of In-Stent Restenosis in a Coronary Artery |
| Q35125781 | Sirolimus in liver transplantation |
| Q31112412 | Sirolimus inhibits key events of restenosis in vitro/ex vivo: evaluation of the clinical relevance of the data by SI/MPL- and SI/DES-ratios |
| Q35125774 | Sirolimus therapy in cardiac transplantation |
| Q36735324 | Sirolimus-Eluting Stents vs Uncoated Stents for the Treatment of Proximal Left Anterior Descending Coronary Artery Stenosis |
| Q36013104 | Sirolimus-eluting coronary stents: a review |
| Q37347010 | Smooth muscle Notch1 mediates neointimal formation after vascular injury |
| Q35925223 | Smooth muscle cell signal transduction: implications of vascular biology for vascular surgeons. |
| Q74180219 | Smooth muscle cells on the move: the battle for actin |
| Q34470332 | Stent development and local drug delivery |
| Q39594283 | Stent elution rate determines drug deposition and receptor-mediated effects |
| Q37916928 | Stent thrombosis and drug-eluting stents |
| Q34547687 | Stent-based antirestenotic coatings (sirolimus/paclitaxel). |
| Q35569139 | Stent-based immunosuppressive therapies for the prevention of restenosis |
| Q35602577 | Surface engineering of biomaterials with plasma techniques. |
| Q36042601 | TGF-β and Smad3 modulate PI3K/Akt signaling pathway in vascular smooth muscle cells |
| Q84595984 | TNF-α promotes human retinal pigment epithelial (RPE) cell migration by inducing matrix metallopeptidase 9 (MMP-9) expression through activation of Akt/mTORC1 signaling |
| Q92649659 | TOR as a Regulatory Target in Rhipicephalus microplus Embryogenesis |
| Q34294170 | Tailoring mTOR-based therapy: molecular evidence and clinical challenges |
| Q29617473 | Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression |
| Q58691736 | Targeted Treatments for Restenosis and Vein Graft Disease |
| Q35164884 | Targeting the cell cycle machinery for the treatment of cardiovascular disease. |
| Q53535205 | The Suppression of Wound Healing Response with Sirolimus and Sunitinib Following Experimental Trabeculectomy in a Rabbit Model |
| Q46713758 | The critical role of the intrinsic VSMC proliferation and death programs in injury-induced neointimal hyperplasia |
| Q36066019 | The drug-based pipeline against restenosis |
| Q34081387 | The effects of rapamycin on lens epithelial cell proliferation, migration, and matrix formation: an in vitro study |
| Q43211170 | The inhibition of insulin-stimulated proliferation of vascular smooth muscle cells by rosiglitazone is mediated by the Akt-mTOR-P70S6K pathway |
| Q51014960 | The late-phase inflammatory response after drug-eluting stent implantation |
| Q44639010 | The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation |
| Q36215450 | The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent |
| Q24634783 | The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1 |
| Q33200968 | The rapamycin derivative RAD inhibits mesangial cell migration through the CDK-inhibitor p27KIP1. |
| Q34294786 | The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies |
| Q41986003 | The wound healing response after implantation of a drug-eluting stent is impaired persistently in the long term |
| Q35117070 | Therapeutic potential of active stent coating |
| Q35917050 | Therapeutic potential of oral antiproliferative agents in the prevention of coronary restenosis |
| Q45864387 | Transgene delivery of plasmid DNA to smooth muscle cells and macrophages from a biostable polymer-coated stent |
| Q34434684 | Tumor Suppressor Serine/Threonine Kinase LKB1 Expression, Not Kinase Activity, Increased in the Vascular Smooth Muscle Cells and Neointima in the Rat Carotid Artery Injury Model |
| Q47250702 | Upregulation of miR-221 and -222 in response to increased extracellular signal-regulated kinases 1/2 activity exacerbates neointimal hyperplasia in diabetes mellitus |
| Q38739534 | Use of Brilliant Blue FCF during vein graft preparation inhibits intimal hyperplasia |
| Q44438446 | Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy |
| Q44437979 | Use of rapamycin-impregnated stents in coronary arteries |
| Q34986363 | Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. |
| Q37843083 | Vascular smooth muscle cell proliferation in restenosis |
| Q39659901 | Water soluble polymer films for intravascular drug delivery of antithrombotic biomolecules |
| Q74117292 | [The Ravel trial. Zero percent restenosis: A cardiologists dream comes true!] |
| Q40835435 | alpha 2 integrin subunit cytoplasmic domain-dependent cellular migration requires p38 MAPK. |
| Q37885070 | mTOR and the differentiation of mesenchymal stem cells. |
| Q37763231 | mTOR signaling in cancer cell motility and tumor metastasis |
| Q34504964 | microRNAs Distinctively Regulate Vascular Smooth Muscle and Endothelial Cells: Functional Implications in Angiogenesis, Atherosclerosis, and In-Stent Restenosis |
Search more.